Interested in the 4d Pharma share price? Here’s what you need to know

The 4d Pharma share price has surged. But is the company still worth buying after this performance, or should it be avoided?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The 4d Pharma (LSE: DDDD) share price has surged in value since the middle of July. Shares in the early-stage biotech business have risen around 200% during the past six weeks.

The performance has put the company on the radar of most small-cap investors. This improving investor sentiment towards the business could send the 4d Pharma share price even higher in the coming weeks and months.

As such, if you’re interested in owning a share of this high-growth small-cap, here’s what you need to know before investing. 

Interested in the 4d Pharma share price?

Shares in this early-stage biotechnology business have rallied over the past six months on the back of two developments

First off, in the middle of July, the company raised nearly £8m to fund its operations until the beginning of 2021. According to management, the funds will be used for at least four clinical studies of treatments in the pipeline. These include 4d’s MRx-4DP0004 Phase II Covid-19 trial and its MRx0518 Phase I clinical biomarker study. 

The company was also planning to use some of the funding to pursue a US market listing. I think this is a sensible decision. US-listed pharmaceutical and biotechnology businesses tend to attract higher valuations as this increases the number of investors who can buy the shares. US listings also make companies more attractive as acquisition targets. 

The second development that has helped the 4d Pharma share price recently is the publication of the results from a recent trial of its MRx0518 treatment. This product is a “single strain live biotherapeutic” that has the potential to help people with cancer.

The results of Part A of its Phase I/II trial were positive. Nearly half of the trial participants saw a “meaningful benefit” from the drug when combined with another treatment. A quarter of the participants saw their tumours shrink by around 30%.

These results are positive, but they are not conclusive. The study only involved 12 subjects. So, a lot more work needs to be done before 4d Pharma can bring the product to market. 

Still, these early results are encouraging. They should help improve investor sentiment towards the business, which could lead to greater access to funding in the months and years ahead. 

High risk

While the above might have sent the 4d Pharma share price surging in recent weeks, there’s no guarantee this will continue. The company’s recent fundraising showed that the business is still not self-sufficient. It is unlikely to be so until its primary treatments come to market. That could take years. 

As such, while the 4d Pharma share price may look attractive at current levels, I think it may be best to hold the stock as part of a diversified portfolio. Doing so would allow investors to profit from any upside growth while minimising downside risk. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »